FDA OKs ViiV Healthcare's HIV Medication For Infants And Children

Pharmaceutical company ViiV Healthcare Ltd. said the U.S. Food and Drug Administration (FDA) approved its Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for oral suspension to treat human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients at least four weeks old and weighing at least 3 kg or 6.61 pounds in combination with other antiretroviral treatments.

from RTT - Biotech https://ift.tt/2N5mG0B
via IFTTT